한국형 양극성 장애 약물치료 알고리듬 2022: 동반 신체질환

초록

Objectives The present study was carried out to revise the guidelines for the Korean Medica tion Algorithm Project for Bipolar Disorder (KMAP-BP) 2018. The revision was carried out based on expert opinions to facilitate clinical decisions related to the treatment of bipolar disorders in patients with comorbid physical illnesses. Methods A 56-item questionnaire was developed; a consensus was arrived at by 87 out of 93 experts (93.5%), on the pharmacological treatment strategies to be used in cases of comorbid physical illnesses accompanying bipolar disorders. Results For patients with bipolar disorder exhibiting comorbid conditions, by consensus, la motrigine, aripiprazole, and ziprasidone were recommended as the first-line strategies for metabolic syndrome; lamotrigine and aripiprazole were the recommended first-line strategies for cardiovas cular problems; lithium and aripiprazole were the recommended first-line strategies for haptic problems; valproate, lamotrigine, aripiprazole, and quetiapine were the recommended first-line strategies for renal problems; and valproate and aripiprazole were the recommended first-line strategies for cerebrovascular problems or cerebral damage. Conclusion The present study is the most recent consensus among experts on recommenda tions for the treatment of bipolar disorders in patients with comorbid physical illnesses. Aripipra zole was recommended as the first-line pharmacotherapeutic agent in five comorbid physical conditions. This recommendation is similar to KMAP-BP 2018. Additionally, lamotrigine has been added as a first -line pharmacotherapeutic agent in patients with the metabolic syndrome, car diovascular problems, and renal problems in the current algorithm.

키워드